Distilling Modern Medical Approaches in Advanced NSCLC: Precision, Performance, and Parallels With Patients

 
Share
 

Manage episode 233103222 series 1452688
By Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio streamed directly from their servers.
Host: Robert Mocharnuk, MD
Guest: Joshua Bauml, MD
Lung and bronchus cancer remain the leading cause of cancer-related deaths in the United States among both men and women. The discovery of predictive biomarkers, such as sensitizing epidermal growth factor receptor (EGFR) mutations, the anaplastic lymphoma kinase (ALK) fusion oncogene, ROS1 gene rearrangements, and BRAF has led to an improvement in overall survival and progression-free survival by identifying subgroups of patients who benefit from targeted treatment; however, most NSCLC tumors lack these mutations.

NSCLC is a highly active research area and its treatment is rapidly evolving. The algorithm for the treatment of metastatic NSCLC has become increasingly complex as new therapies are being developed, including advances in the treatment of patients with metastatic NSCLC without targetable activating mutations that has progressed on prior platinum-based therapy, or chemotherapy in combination with immunotherapy, including NSCLC that has progressed rapidly on initial therapy.

Through real-world clinical cases, this activity will review available treatment options and guideline recommendations for patients with advanced NSCLC without targetable activating mutations that has progressed on initial platinum-based therapy, or immunotherapy combined with chemotherapy, and available data that can inform treatment of NSCLC that progresses rapidly on initial therapy. Discussion will include real-world patient ...

140 episodes available. A new episode about every 0 hours averaging 0 mins duration .